Phenomic AI
Click to visit website
About
Phenomic AI is a biotechnology company dedicated to improving survival rates for patients with the most challenging solid tumors, such as pancreatic, colorectal, and breast cancers. The company addresses a fundamental gap in traditional drug discovery: many therapeutic candidates fail in clinical trials because they were developed using models that overlook the intricate diversity of cell types found in human tumors. To bridge this gap, Phenomic has developed an advanced machine learning-powered transcriptomics platform, known as scTx, designed to interrogate single-cell RNA data at a large scale. By analyzing the interactions between various cell types within a tumor, the platform identifies novel targets that traditional methods might miss. The scTx platform functions by integrating multiple data streams, including imaging, RNA sequencing, and spatial transcriptomics. This multi-modal approach allows researchers to explore cell type and target expression profiles in high resolution within both human cancer samples and normal tissue. Beyond simple identification, Phenomic utilizes a system to test potential drugs in human tumor explants and animal models, providing critical translational insights early in the discovery process. This method focuses heavily on the tumor stroma—the connective tissue within a tumor—which frequently acts as a barrier to the efficacy of existing medicines. The primary users and beneficiaries of this technology are large pharmaceutical companies and biotechnology firms seeking to develop first-in-class therapies. Phenomic operates through strategic research collaborations, as evidenced by their high-value agreements with industry leaders like Boehringer Ingelheim and Astellas Pharma. These partnerships leverage Phenomic’s expertise in stromal biology and antibody discovery to enhance cell therapy approaches and discover new targets for stroma-rich cancers. The tool is best suited for drug development teams aiming to overcome resistance mechanisms in solid tumors. What distinguishes Phenomic AI from other biotech firms is its deep integration of machine learning with specialized knowledge of the tumor microenvironment. The company is led by a team of biopharma veterans and advised by world-renowned experts, including Nobel Laureate James Allison. Their lead program, a CD3 engager, serves as a proof-of-concept for their platform, demonstrating the ability to identify high-impact, druggable targets that overcome the limitations of traditional tumor-associated antigens. This combination of proprietary AI technology and expert scientific oversight positions the platform as a significant player in the next generation of precision oncology discovery.
Pros & Cons
Leverages single-cell RNA data to provide high-resolution insights into target expression and selectivity.
Focuses specifically on the tumor stroma to overcome traditional barriers in solid tumor treatment.
Supported by a scientific advisory board that includes a Nobel Prize winner and leaders in immune-oncology.
Demonstrated commercial viability through a target identification deal worth over $500 million.
Utilizes spatial transcriptomics to understand the biology of single cells within complex multi-cell systems.
Lead therapeutic programs are currently at the development candidate or pre-clinical stage rather than in clinical trials.
The platform is currently focused exclusively on solid tumors, limiting its application for other types of cancer.
Access to the platform is limited to strategic enterprise partnerships rather than being available as a software tool.
Success of the platform's insights depends on the availability of high-quality human tissue and single-cell data samples.
Use Cases
Pharmaceutical research teams can leverage the scTx platform to identify novel antibody targets in stroma-rich tumors that have failed traditional discovery methods.
Biotech companies specializing in cell therapy can partner with Phenomic to enhance their existing programs using antibodies directed at novel stromal targets.
Oncology researchers can use the platform's spatial transcriptomics capabilities to understand complex cell-cell interactions within human tumor explants.
Platform
Task
Features
• translational discovery insights
• human tumor explant testing
• antibody drug discovery
• tumor stroma targeting
• imaging data processing
• spatial transcriptomics
• single-cell rna analysis
• ml-powered transcriptomics
FAQs
What is the primary focus of Phenomic's scTx platform?
The platform uses machine learning to interrogate single-cell RNA data and spatial transcriptomics to identify drug targets in the tumor stroma. It aims to solve the problem of poor drug translation by accounting for the diversity of cell types in solid tumors.
What kind of data does Phenomic AI process?
The system is designed to handle imaging, RNA sequencing, and spatial transcriptomics data from human cancer samples and disease-relevant experimental systems. This allows for a detailed exploration of cell type and target expression profiles.
Has Phenomic AI established any industry partnerships?
Yes, the company has significant collaborations with Boehringer Ingelheim for target discovery in stroma-rich cancers and Astellas Pharma for solid tumor cell therapies. One deal with Boehringer Ingelheim is valued at over $500 million.
What is the status of Phenomic AI's lead program?
Their lead program is a CD3 engager targeting a novel approach identified by their platform. It is currently at the development candidate stage, showing compelling results in challenging cancer models.
Who comprises the scientific leadership at Phenomic?
The company is led by CEO Girish Aakalu and CTO Sam Cooper, with an advisory board featuring Nobel Laureate James Allison and other pioneers in immune-oncology and machine learning.
Pricing Plans
Strategic Partnership
Unknown Price• Target identification
• scTx platform access
• Antibody discovery
• Stromal biology expertise
• Translational discovery insights
• Human tumor explant testing
Job Opportunities
Senior Data Scientist
Identify novel therapeutic targets for hard-to-treat solid tumors by using an ML-powered transcriptomics platform to analyze single-cell RNA and stromal biology.
Education Requirements:
Ph.D. in Bioinformatics, Computational Biology, Statistics, Computer Science, or a related field
Experience Requirements:
3-5 years of relevant experience in Industry or a relevant academic lab in a Post-doc position
Proficiency in Python programming language
Experience in analyzing scRNA-seq data
Strong publication record
Other Requirements:
Expertise in cancer biology
Strong background in statistics, machine learning, and data visualization
Familiarity with cloud computing platforms and version control systems (e.g., Git)
Responsibilities:
Collaborate with the biology team, senior management, informatics team, and partners to analyze data and derive insights
Design, implement, and optimize computational pipelines for analyzing large-scale single-cell RNA sequencing (scRNA-seq) datasets
Develop and apply novel statistical and machine learning approaches to identify cell types and states
Integrate scRNA-seq data with other omics data to enhance understanding of cellular heterogeneity
Stay up-to-date with developments in single-cell genomics and data science to contribute to the scientific community
Show more details
Ratings & Reviews
No ratings available yet. Be the first to rate this tool!
Alternatives
X-Chem
X-Chem accelerates small molecule drug discovery by combining DEL technology with AI solutions. Their ArtemisAI platform powers HITMiner for molecular interaction mapping and hit expansion.
View Details
BenevolentAI
BenevolentAI uses AI for drug discovery and development, partnering with pharma companies to tackle complex diseases and accelerate drug development timelines.
View Details
Aitia Bio
Aitia Bio uses AI, multi-omic data, and Gemini Digital Twins to accelerate drug discovery and development, focusing on oncology and neurodegenerative diseases.
View Details
Aganitha AI
Aganitha AI is an in silico company that partners with biopharma, personal & homecare, and material sciences industries, leveraging AI to accelerate scientific R&D.
View Details
MindRank
Accelerate small molecule drug discovery and tackle hard-to-drug targets using a clinical-stage AI platform designed for biotech and pharmaceutical researchers.
View Details
Delta4
Identify new therapeutic indications for existing compounds using an AI-powered systems biology platform to reduce R&D costs and accelerate time-to-market.
View Details
ALS.ai
Accelerate ALS drug discovery and target identification using deep generative models and multi-omics data analysis to find novel therapeutics for patients.
View Details
canSAR.ai
canSAR.ai is an integrated knowledge-base leveraging machine learning and AI for cancer drug discovery and translational research worldwide.
View Details
biotx.ai
Help pharmaceutical researchers accelerate drug discovery and minimize clinical trial failure by mapping causal genetic links using AI-driven Mendelian randomization.
View Details
Proxima
Design programmable protein interactions and discover next-generation proximity-based medicines using an integrated AI platform for biopharmaceutical research.
View Details
Iktos
Accelerate drug discovery by integrating generative AI with automated robotics to design, synthesize, and test novel molecules in under two years for pharma teams.
View Details
Atomic AI
Accelerate RNA drug discovery using a foundation model that predicts 3D structures with atomic precision to unlock previously inaccessible therapeutic targets.
View Details
Iambic
Design superior therapeutic molecules and accelerate drug discovery using physics-based AI algorithms and high-throughput experimental feedback loops.
View Details
GSK.ai
Accelerate drug discovery and vaccine development by leveraging AI to interpret complex genetic datasets and understand the fundamental language of human cells.
View Details
Cognit
Accelerate functional genomics research and simulate complex gene regulatory networks using cross-species foundational AI models for in-silico cell engineering.
View Details
Gero
Extend healthy human lifespan and discover novel therapeutic targets using physics-informed AI models trained on over 100 million longitudinal medical records.
View Details
Receptor.AI
Optimize early-stage drug discovery for biotech researchers using an AI ecosystem that identifies cryptic binding sites and predicts over 80 ADMET endpoints.
View Details
Wisecube
Accelerate life sciences R&D using a foundational graph AI that unifies billions of biomedical data points to provide reliable, literature-backed insights.
View Details
Pending AI
Empower drug discovery teams to unlock difficult-to-drug targets and optimize lead candidates using quantum mechanical precision and trillion-scale generative AI.
View DetailsFeatured Tools
adly.news
Connect with engaged niche audiences or monetize your subscriber base through an automated marketplace featuring verified metrics and secure Stripe payments.
View Details
Image to Image AI
Transform photos and videos using advanced AI models for face swapping, restoration, and style transfer. Perfect for creators needing fast, professional visuals.
View Details
Nano Banana
Edit and enhance photos using natural language prompts while maintaining character consistency and scene structure for professional marketing and digital art.
View Details
Nana Banana Pro
Maintain perfect character consistency across diverse scenes and styles with advanced AI-powered image editing for creators, marketers, and storytellers.
View Details
Kling 4.0
Transform text and images into cinematic 1080p videos with multi-shot storytelling, character consistency, and native lip-synced audio for professional creators.
View Details
AI Seedance
Generate 15-second cinematic 2K videos with physics-based audio and multi-shot narratives from text or images. Ideal for creators and marketing teams.
View Details
Mistrezz.AI
Engage in immersive NSFW roleplay and ASMR voice sessions with adaptive AI companions designed for structured escalation, fantasy scenarios, and personal connection.
View Details
Seedance 3.0
Transform text prompts or static images into professional 1080p cinematic videos. Perfect for creators and marketers seeking high-quality, physics-aware AI motion.
View Details
Seedance 3.0
Transform text descriptions into cinematic 4K videos instantly with ByteDance's advanced AI, offering professional-grade visuals for creators and marketing teams.
View Details
Seedance 2.0
Generate broadcast-quality 4K videos from simple text prompts with precise text rendering, high-fidelity visuals, and batch processing for content creators.
View Details
BeatViz
Create professional, rhythm-synced music videos instantly with AI-powered visual generation, ideal for independent artists, social media creators, and marketers.
View Details
Seedance 2.0
Generate cinematic 1080p videos from text or images using advanced motion synthesis and multi-shot storytelling for marketing, social media, and creators.
View Details